Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages 6568-6578

  Friedman, Jay ^a   Nottingham, Liesl ^a   Duggal, Praveen ^a   Pernas, Francisco G ^a   Yan, Bin ^a   Xin, Ping Yang ^a   Chen, Zhong ^a   Van Waes, Carter ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMALARIAL AGENT; CISPLATIN; DOXORUBICIN; MEPACRINE; MESSENGER RNA; PIFITHRIN ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL FUNCTION; CELL LINE; CELL PROLIFERATION; CYTOTOXICITY; DNA BINDING; DRUG EFFECT; DRUG SENSITIVITY; GENE EXPRESSION; GENE FUNCTION; GENOTOXICITY; GENOTYPE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; QUINACRINE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 36749031733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1591     Document Type: Article

References (49)

1. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007;26:1306-16.
2. Kastan MB. Wild-type p53: tumors can't stand it. Cell 2007;128:837-40.
3. Hardisson D. Molecular pathogenesis of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2003;260:502-8.
4. Mao L, Hong WK, Papadimitrakopoulou VA. Focus on head and neck cancer. Cancer Cell 2004;5:311-6.
5. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl JMed 2001;345:1890-900.
6. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 1999;30:1221-5.
7. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Cancer Study Group. Otolaryngol Head Neck Surg 1995;113:408-12.
8. Hsu CH, Chen CL, Hong RL, Chen KL, Lin JF, Cheng AL. Prognostic value of multidrug resistance 1, glutathione-S-transferase-π and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy. Oncology 2002;62:305-12.
9. Kumar B, Cordell KG, D'Silva N, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. American Head and Neck Society 2006 Annual Meeting & Research Workshop; 2006.
10. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-61.
11. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004;96:998-1006.
12. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56.
13. Yeh KT, Chang JG, Lin TH, et al. Epigenetic changes of tumor suppressor genes, P15, P16, VHL and P53 in oral cancer. Oncol Rep 2003;10:659-63.
14. Bolt J, Vo QN, Kim WJ, et al. The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 2005;41:1013-20.
15. Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996;56:3630-3.
16. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck. Virchows Arch 2002;441:133-42.
17. McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for reversal by 5-azacytidine. Cancer Res 2002;62:4757-66.
18. Zhu WG, Hileman T, Ke Y, et al. 5-aza-2′-deoxycytidine activates the p53/p21 Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 2004;279:15161-6.
19. Bradford CR, Zacks SE, Androphy EJ, Gregoire L, Lancaster WD, Carey TE. Human papillomavirus DNA sequences in cell lines derived from head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 1991;104:303-10.
20. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993;8:307-18.
21. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004;279:53272-81.
22. Gurova KV, Hill JE, Guo C, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A 2005;102:17448-53.
23. Wang W, Ho WC, Dicker DT, et al. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther 2005;4:893-8.
24. Chen Z, Malhotra PS, Thomas GR, et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999;5:1369-79.
25. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001;61:5911-8.
26. Yu M, Yeh J, VanWaes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serumfactor(s) in head and neck squamous carcinoma cells. Cancer Res 2006;66:6722-31.
27. Yan B, Yang X, Lee TL, et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, NF-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007;8:R78.
28. Worden B, Yang XP, Lee TL, et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through Egr-1 in head and neck squamous cell carcinoma. Cancer Res 2005;65:7071-80.
29. Lee TL, Yeh J, Van Waes C, Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 2006;5:8-19.
30. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005;207:251-9.
31. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 2002;14:86-91.
32. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
33. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999;285:1733-7.
34. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-3.
35. Li SL, Kim MS, Cherrick HM, Park NH. Low p53 level in immortal, non-tumorigenic oral keratinocytes harboring HPV-16 DNA. Eur J Cancer B Oral Oncol 1992;28B:129-34.
36. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
37. Tergaonkar V, Pando M, Vafa O, Wahl G, Verma I. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 2002;1:493-503.
38. Raman V, Martensen SA, Reisman D, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000;405:974-8.
39. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
40. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674-7.
41. Webster GA, Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 1999;19:3485-95.
42. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:1951-8.
43. Lee TL, Yang XP, Yan B, et al. A novel NF-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007;13:5680-91.
44. Denny, WA. Acridine derivatives as chemotherapeutic agents. Curr Med Chem 2002;9:1655-65.
45. Denny WA, Cain BF, Atwell GJ, Hansch C, Panthananickal A, Leo A. Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents. J Med Chem 1982;25:276-315.
46. Legha SS, Gutterman JU, Hall SW, et al. Phase 1 clinical investigation of 4′-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative. Cancer Res 1978;38:3712-6.
47. Cabanillas F, Legha SS, Bodey GP, Freireich EJ. Initial experience with AMSA as single agent treatment against malignant lymphoproliferative disorders. Blood 1981;57:614-6.
48. Sebolt JS, Scavone SV, Pinter CD, Hamelehle KL, Von Hoff DD, Jackson RC. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 1987;47:4299-304.
49. Rowinsky EK, Noe DA, Grochow LB, et al. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol 1995;13:1975-84.